Accuray has reported that Mount Vernon Cancer Centre in the UK will acquire a CyberKnife Robotic Radiosurgery System.
The company said that the CyberKnife System uses real-time tracking capabilities to deliver high-dose radiation to tumors, which also include tumors that move with respiration.
The company also claims that CyberKnife System does not use stabilising frames or breath holding techniques, making it easy for the patient. Treatments are completed in one to five days and patients can resume their normal activities immediately following treatment.
Peter Ostler, consultant for clinical oncologist and clinical chair for cancer services at the Trust, said: “Patients have been eager to see CyberKnife radiosurgery available through the National Health Service, so we are excited to soon be able to offer them this form of cancer care. The CyberKnife System will enable us to expand our radiation offerings to patients who may not have been able to tolerate other treatments or have medically or surgically inoperable tumors.”
Euan Thomson, president and CEO of Accuray, said: “Mount Vernon Cancer Centre has a strong reputation for cancer treatment, particularly using radiation, so it is great to see their treatment arsenal strengthened with the purchase of a CyberKnife System. We are proud to be working with the East and North Hertfordshire NHS Trust and are very pleased with their recognition of the CyberKnife System’s contributions in the treatment of cancer.”
East and North Hertfordshire NHS Trust manages four hospitals, including the Mount Vernon Cancer Centre. The Mount Vernon Cancer Centre, which is located in North-west London, provides tertiary radiotherapy services, and also a local chemotherapy service.